Profit from the Biotech Bounce

LAS VEGAS, NV / ACCESSWIRE / May 3, 2016 / After falling more than 40% from its peak in July until reaching its bottom in February, the biotech sector has put together an almost 15% rally from its lows. Several indications suggest this upward trend has occurred and remains likely to continue. Among them include sector overselling, increased M&A chatter and one of the few sectors seeing real revenue and earnings growth right now.

With that said, it is an opportune time to find underpriced growth companies in the biotech sector poised to breakout. One opportunity looking particularly exciting is Endonovo Therapeutics, Inc. (ENDV), a biotechnology company developing bioelectronic products and therapies for regenerative medicine. Endonovo's Immunotronics? platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics? platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company's initial concentration is on the treatment of acute inflammatory conditions of the liver using its proprietary Immunotronics? platform.

Bioelectronics present one of the most attractive growth opportunities for potential biotech investors. This area focuses on the study and application of electronics in medicine and biological processes. The market for bioelectronics was valued at $43 billion in 2015 and is expected to reach $77.4 billion in 2021, growing at a CAGR of 14% from 2015-2021, according to Occams Business Research.

The timing is particularly good for investing in ENDV as they just announced Chairman & CEO Alan Collier will be presenting a company and bioelectronics overview at the SeeThruEquity 5th Annual Microcap Investor Conference on May 31, 2016. The event will be held at Convene Conference Center at 730 3rd Avenue in New York City.

Presentations like these have preceded some major runs as they become major awareness drivers. Investors at the conference learning about ENDV should like what they hear. The company just received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." When the USPTO intends to issue a patent, it sends the applicant a Notice of Allowance, which is what ENDV just received. The final steps required before the actual patent is issued are essentially a formality (applicant pays required issue fee and submits any final drawings). So essentially this news means ENDV has received patent approval.

The patent application covers the production of biological molecules, including growth factors and cytokines in adult stem cells using the Company's proprietary technologies. The Company stated in its press release some of the technology's applications include the production of fully human proteins for research purposes or the potential production of next-generation biologics. Conventional methods used to produce therapeutic proteins such as biological drugs include recombinant techniques used with bacteria, eukaryotic or Chinese Hamster Ovary (CHO) cells.

According to Thomson Reuters, the biologics sector is set for an unprecedented level of activity as U.S. companies have rapidly increased biologics development during the past five years. The market for next-generation biologics is estimated to reach a value of $30 billion by 2024, according to Visiongain. These next-generation biologics will seek to address shortcomings in current therapies, including inconvenient dosing and potential side-effects.

A few other biotech companies gaining interest and worth a look include; (RPRX), Ampio Pharmaceuticals, Inc. (AMPE), BioDelivery Sciences International, Inc. (BDSI), Rockwell Medical, Inc. (RMTI), and Keryx Biopharmaceuticals, Inc. (KERX), Ignyta, Inc. (RXDX).

ENDV, however, out of all of these companies has had probably the most impressive year so far and looks poised to continue this trend moving forward. It would be wise to start researching Endonovo today.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC., which owns Microcapspeculators.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC., which owns Microcapspeculators.com, may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $26,000 cash by a non-affiliate third party of ENDV.

Contact:

Acrlasvegas@gmail.com

SOURCE: ACR Communication, LLC